Get the Stockscreener App
1.51
3.21%
-0.05
Pre-market:
1.50
-0.01
-0.66%
Marker Therapeutics Inc stock is traded at $1.51, with a volume of 102.57K.
It is down -3.21% in the last 24 hours and up +14.39% over the past month.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
See More
Previous Close:
$1.56
Open:
$1.59
24h Volume:
102.57K
Relative Volume:
0.70
Market Cap:
$25.18M
Revenue:
$3.55M
Net Income/Loss:
$-12.16M
P/E Ratio:
-1.6603
EPS:
-0.9095
Net Cash Flow:
$-12.01M
1W Performance:
+6.34%
1M Performance:
+14.39%
6M Performance:
+64.65%
1Y Performance:
+22.76%
1-Day Range:
$1.45
$1.60
1-Week Range:
$1.3701
$1.60
52-Week Range:
$0.8099
$4.07
Marker Therapeutics Inc Stock (MRKR) Company Profile
Name
Marker Therapeutics Inc
Sector
Industry
Phone
(713) 400-6400
Address
2450 HOLCOMBE BLVD, HOUSTON, TX
Compare MRKR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRKR
Marker Therapeutics Inc
|
1.51 | 25.18M | 3.55M | -12.16M | -12.01M | -0.9095 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Marker Therapeutics Inc Stock (MRKR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Initiated | Canaccord Genuity | Buy |
| Mar-25-21 | Initiated | Piper Sandler | Overweight |
| Mar-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-12-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| Mar-01-19 | Initiated | Janney | Buy |
| Dec-03-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
View All
Marker Therapeutics Inc Stock (MRKR) Latest News
MSN Money - MSN
Marker Therapeutics (NASDAQ: MRKR) holders back share increase but reject voting change - Stock Titan
Marker Therapeutics, Inc. (MRKR) reports Q4 loss, tops revenue estimates - MSN
Is Marker Therapeutics (MRKR) stock moving unpredictably (Ticks Down) 2026-04-24Popular Trader Picks - Newser
Is Marker Therapeutics (MRKR) stock worth buying today | Q4 2025: EPS Exceeds ExpectationsFinancial Data - Cổng thông tin điện tử tỉnh Lào Cai
Stock List: Research Stocks from Around the World - GuruFocus
Ideas Watch: What are Marker Therapeutics Incs growth levers2026 Spike Watch & Safe Capital Preservation Plans - baoquankhu1.vn
Published on: 2026-04-06 22:29:12 - baoquankhu1.vn
Can Marker Therapeutics (MRKR) Stock Rebound in 2026 | Price at $1.44, Up 9.09%Sell Signals - Cổng thông tin điện tử Tỉnh Sơn La
Total debt per share of Marker Therapeutics, Inc. – FWB:GX1 - TradingView
EBITDA per share of Marker Therapeutics, Inc. – FWB:GX1 - TradingView
Marker Therapeutics, Inc. (MRKR) stock price, news, quote and history - Yahoo Finance UK
EPS Watch: What is the long term forecast for Marker Therapeutics Inc stock2026 Volatility Report & Low Risk High Win Rate Picks - baoquankhu1.vn
Is Marker Therapeutics (MRKR) Stock Leading the Market | Price at $1.77, Up 1.14%Trending Momentum Stocks - UBND thành phố Hải Phòng
Exploring Three High Growth Tech Stocks In The US Market - simplywall.st
MRKR SEC FilingsMarker Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
Insider Sell: Can Marker Therapeutics Inc deliver consistent dividends2026 Fed Impact & Free Reliable Trade Execution Plans - baoquankhu1.vn
Exit Recap: Should I hold or sell Marker Therapeutics Inc now2026 Institutional Moves & Low Risk High Reward Ideas - baoquankhu1.vn
H.C. Wainwright reiterates Marker Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Marker Therapeutics (MRKR) to Release Quarterly Earnings on Monday - Defense World
Marker Therapeutics (NASDAQ:MRKR) & Prelude Therapeutics (NASDAQ:PRLD) Financial Survey - Defense World
Q2 Earnings Estimate for MRKR Issued By Brookline Cap M - Defense World
Form DEF 14A Marker Therapeutics For: 20 March - Investing.com
Marker Therapeutics (NASDAQ: MRKR) proxy eyes 130M shares, lower vote hurdle - Stock Titan
MRKR PE Ratio & Valuation, Is MRKR Overvalued - Intellectia AI
[ARS] Marker Therapeutics, Inc. SEC Filing - Stock Titan
Marker Therapeutics Highlights Strong MT-601 Data and Prepares for Key 2026 Milestones - TipRanks
Marker Therapeutics, Inc. 2025 10-K: Clinical-Stage Immuno-Oncology Pipeline, Regulatory Strategy, and Competitive Landscape Overview - Minichart
MARKER THERAPEUTICS, INC. (MRKR) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Marker Therapeutics (MRKR) outlines MAR-T cancer pipeline, MT-601 trials and grant funding - Stock Titan
Marker Therapeutics 10-K: Revenue $3.55M; Net loss $12.18M - TradingView
Marker Therapeutics 2025 net loss widens, hurt by decline in grant income - TradingView
Marker Therapeutics Reports Encouraging Phase 1 APOLLO Data and Corporate Developments in Immuno-Oncology - Quiver Quantitative
MRKR: Net loss widened to $12.2M in 2025 as clinical programs advanced, with cash runway through Q4 2026 - TradingView
Marker Therapeutics (NASDAQ: MRKR) reports 2025 loss and cash runway into late 2026 - Stock Titan
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results - GlobeNewswire
Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Pullback Watch: Can Marker Therapeutics Inc outperform in the next rally2026 Support & Resistance & High Accuracy Investment Signals - baoquankhu1.vn
Marker Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Tangible book value per share of Marker Therapeutics, Inc. – MUN:GX1 - TradingView
Aug Weekly: What is the long term forecast for Marker Therapeutics Inc stockPrice Action & AI Driven Stock Reports - baoquankhu1.vn
H.C. Wainwright Sticks to Its Buy Rating for Marker Therapeutics (MRKR) - The Globe and Mail
Marker Therapeutics (NASDAQ: MRKR) seeks approval to raise authorized shares to 130M - Stock Titan
Will Marker Therapeutics Inc. stock outperform value stocks2025 Big Picture & Weekly Momentum Stock Picks - Naître et grandir
Market Pulse: Does Marker Therapeutics Inc have pricing powerJuly 2025 Reactions & Smart Allocation Stock Tips - baoquankhu1.vn
What is the long term forecast for Marker Therapeutics Inc stockPortfolio Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
MRKR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
MRKR: First-in-class MAR-T cell therapy shows high efficacy and safety in refractory lymphoma - TradingView
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - The Manila Times
How buybacks impact Marker Therapeutics Inc. stock value2025 Top Decliners & AI Based Buy/Sell Signal Reports - mfd.ru
Marker Therapeutics Inc Stock (MRKR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):